Denali Therapeutics (NASDAQ:DNLI) Price Target Cut to $30.00 by Analysts at Wedbush

Denali Therapeutics (NASDAQ:DNLIFree Report) had its target price cut by Wedbush from $31.00 to $30.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Denali Therapeutics’ FY2028 earnings at $1.74 EPS.

Other analysts have also issued reports about the stock. Stifel Nicolaus dropped their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a hold rating on the stock in a research report on Wednesday. The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a buy rating for the company in a research note on Thursday, February 29th. UBS Group lowered their price target on Denali Therapeutics from $70.00 to $32.00 and set a buy rating on the stock in a research report on Tuesday, April 9th. Finally, HC Wainwright reaffirmed a buy rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Denali Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $40.22.

Get Our Latest Analysis on Denali Therapeutics

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $18.31 on Wednesday. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.31. The company has a market cap of $2.61 billion, a P/E ratio of -19.07 and a beta of 1.39. The stock’s 50-day simple moving average is $18.72 and its 200 day simple moving average is $18.83.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter last year, the business posted ($0.80) EPS. As a group, equities analysts predict that Denali Therapeutics will post -2.7 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $18.37, for a total value of $30,604.42. Following the transaction, the director now owns 121,375 shares of the company’s stock, valued at $2,229,658.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Denali Therapeutics news, Director Steve E. Krognes sold 2,750 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the sale, the director now owns 139,841 shares of the company’s stock, valued at approximately $2,417,850.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $18.37, for a total transaction of $30,604.42. Following the transaction, the director now owns 121,375 shares in the company, valued at approximately $2,229,658.75. The disclosure for this sale can be found here. Insiders sold a total of 110,955 shares of company stock worth $2,218,802 over the last quarter. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently added to or reduced their stakes in the stock. CWM LLC raised its holdings in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after acquiring an additional 1,376 shares in the last quarter. Assetmark Inc. raised its stake in Denali Therapeutics by 49.1% in the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after purchasing an additional 707 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the period. Fisher Asset Management LLC bought a new stake in Denali Therapeutics during the fourth quarter worth about $59,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Denali Therapeutics by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after buying an additional 1,732 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Recommended Stories

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.